Navigation Links
Affymax Announces Phase 2 Clinical Trial Results of Once-Per-Month,Hematide for the Treatment of Anemia in Patients with Early- and,End-Stage Chronic Kidney Disease

PALO ALTO, Calif.--(BUSINESS WIRE)--Apr 23, 2007 - Affymax, Inc. (Nasdaq:AFFY) today announced results to date from two separate Phase 2 clinical trials of Hematide(TM) in dialysis and non-dialysis chronic kidney disease (CKD) patients. The data showed that in treatment naive, non-dialysis patients Hematide could correct anemia when administered monthly at an appropriate dose. Similarly, the data in dialysis patients previously treated with three-times weekly Epoetin Alfa demonstrated that mean hemoglobin (Hgb) levels could be maintained at clinically acceptable levels following a switch to once monthly dosing of Hematide at an appropriate dose. The data were presented by Iain C. Macdougall, M.D. at the World Congress of Nephrology meeting being held in Rio de Janeiro.

"These data show that Hematide results in appropriate management of hemoglobin levels in a broad spectrum of patients with CKD from early-stage patients not on dialysis to patients with end-stage renal disease requiring continuous dialysis support," said Dr. Macdougall. "Anemia is a pervasive problem in the chronic kidney disease patient population. Being able to manage and control anemia allows treating physicians to focus attention on management of the patient's underlying renal disease."

At the time of the presentation, the data generated to date were from two multi-center, open-label studies that have enrolled a total of 304 patients. Safety data were based on the entire patient population, while pharmacodynamic data were based on 180 patients who had mostly completed six months of treatment at European and U.S. sites.

Of those, 90 treatment naive CKD patients who were not on dialysis in the correction study were treated with Hematide once every four weeks. The mean Hgb level was 10.2 g/dL at study entry and was increased to greater than 11 g/dL following an initial dose of Hematide. In the maintenance-conversion study, 90 patie
'"/>




Page: 1 2 3

Related medicine technology :

1. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
2. Affymax Announces Results From Phase 2 Clinical Trial of Hematide for the Treatment of Anemia in Dialysis Patients
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:8/29/2014)... DALLAS , Aug. 29, 2014 /PRNewswire-iReach/ -- ... Crystallography Scanner Industry, 2009-2019 is a professional and ... X-Ray Crystallography Scanner industry . The report firstly ... including its classification, application and manufacturing technology. The ... of X-Ray Crystallography Scanner listing their product specification, ...
(Date:8/29/2014)... Aug. 29, 2014  Chuma Holdings, Inc. (OTCBB:CHUM) ... and turnkey support services for the lawfully organized ... processed and approved the Company,s name and symbol ... Corporation will be known as Chuma Holdings, Inc. ... through a merger with the Company,s wholly-owned subsidiary, ...
(Date:8/29/2014)... , Aug. 29, 2014 The clinical ... can be the difference between a product,s success or ... map and stratify KOL targets – and then to ... type of strong relationships upon which successful KOL engagement ... pharma companies have identified internal inconsistencies in their KOL ...
Breaking Medicine Technology:X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 2X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 3X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 5CannaMed Announces Name Change and Trading Symbol Change 2CannaMed Announces Name Change and Trading Symbol Change 3Implementing a Strategic Thought Leader Management & Engagement System 2
... Organogenesis, Inc. announced that its Apligraf® bilayered living cellular construct ... and other chronic wounds by the Saudi Food and Drug ... a living cell based product used by physicians to heal ... world. "With diabetes being a widespread and growing ...
... 28 Boston Scientific Corporation (NYSE: BSX ... long-term data from the MADIT II clinical trial in ... demonstrates that the life-saving benefits of implantable cardioverter defibrillator ... the first time that long-term data regarding the benefits ...
Cached Medicine Technology:Apligraf® Approved by Saudi Food and Drug Authority for Treatment of Chronic Wounds 2Boston Scientific Welcomes Publication of Analysis Demonstrating Long-Term Survival Benefit for ICD Therapy 2Boston Scientific Welcomes Publication of Analysis Demonstrating Long-Term Survival Benefit for ICD Therapy 3
(Date:8/29/2014)... (PRWEB) August 29, 2014 Formed in 2014, ... talents well beyond their years. Their sophisticated Pop/R&B sound, ... music listener is fortunate enough to experience every day. ... their audience uplifted and feeling loved with the primary purpose ... specifically about this, the group unanimously replied - “To make ...
(Date:8/29/2014)... La Mirada, CA (PRWEB) August 29, 2014 ... care which will give patients the convenience of ... consultations with Healthpointe doctors through telemedicine. , Healthpointe doctors ... video calls (or audio). If necessary, the doctor can ... has assessed the patient’s condition, he or she can ...
(Date:8/29/2014)... 29, 2014 A recent article ... by a Tokyo clothing store for men with gynecomastia, or ... rectifying or diminishing their problem. Board-certified plastic surgeon Dr. Chasan ... problem. While many people only associate male breasts with men ... condition among men of all ages, often starting in adolescence. ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Highly regarded audiologist ... on important hearing health topics. The four reports are titled:, ... The Secrets to Hearing Aid Success , The Top ... Understanding Auditory Processing Disorder in Children , ... because there is a lot of confusion and misinformation about each ...
(Date:8/29/2014)... Healthpointe is pleased to announce orthopedic fellowship-trained ... Dr. Chuang garners extensive experience in the field of ... reconstructive treatments of the knees, hips, and shoulders. He ... sports-related orthopedic needs. , Dr. Chuang has ... Orange County native, he graduated with two Bachelor of ...
Breaking Medicine News(10 mins):Health News:KAJ Brothers Commits $10,000 to International Justice Mission To End Human Sex Trafficking and Challenges Other Artists and Celebrities To Do Likewise 2Health News:KAJ Brothers Commits $10,000 to International Justice Mission To End Human Sex Trafficking and Challenges Other Artists and Celebrities To Do Likewise 3Health News:KAJ Brothers Commits $10,000 to International Justice Mission To End Human Sex Trafficking and Challenges Other Artists and Celebrities To Do Likewise 4Health News:Virtual Doctor’s Appointments Now Available at Healthpointe 2Health News:New Bra Created for Men with Gynecomastia, But Will It Work? 2Health News:New Bra Created for Men with Gynecomastia, But Will It Work? 3Health News:Charleston SC Audiologist, Dr. Mary Ann Larkin Authors Four New Special Reports on Important Hearing Healthcare Topics 2Health News:Charleston SC Audiologist, Dr. Mary Ann Larkin Authors Four New Special Reports on Important Hearing Healthcare Topics 3Health News:Healthpointe is Honored to Induct Orthopedic Surgeon into Their Team 2
... By Steven Reinberg HealthDay Reporter , MONDAY, Jan. ... with a small increase in the risk of heart attack, ... in Ohio looked at seven trials involving Pradaxa that included ... data from published clinical trials to tease out a pattern ...
... HealthDay Reporter , MONDAY, Jan. 9 (HealthDay News) -- ... new research that finds losing a loved one can increase ... a significant other,s death, heart attack risk was 21 times ... nearly 2,000 heart attack patients. And within the first week ...
... , MONDAY, Jan. 9 (HealthDay News) -- Nicotine patches and ... therapy" -- don,t help many smokers kick the habit ... This conclusion is based on results of several surveys ... who used nicotine replacement therapy (NRT) did not gain any ...
... Randy Dotinga HealthDay Reporter , MONDAY, Jan. 9 ... used by people trying to quit smoking could serve an ... older patients. The research is preliminary and only involved ... While they,re available over the counter, patches may cost several ...
... -- A 2010 outbreak of Legionnaires, disease in Wisconsin ... hospital lobby, according to a study published in the ... , the journal of the Society for Healthcare Epidemiology ... was detected among eight people in southeast Wisconsin, state ...
... (HealthDay News) -- Waiting up to a year to treat ... not harmful, but waiting many years to get blood pressure ... In the study, published online Jan. 9 in the ... University of Chicago suggested that the one-year delay could give ...
Cached Medicine News:Health News:New Blood Thinner Linked to Higher Heart Attack Risk 2Health News:New Blood Thinner Linked to Higher Heart Attack Risk 3Health News:Grief Is a Real Heartbreaker, Study Finds 2Health News:Grief Is a Real Heartbreaker, Study Finds 3Health News:Nicotine Patches, Gums Won't Help Smokers Quit Long-Term: Study 2Health News:Nicotine Patches, Gums Won't Help Smokers Quit Long-Term: Study 3Health News:Could Nicotine Patches Help Stave Off Memory Loss? 2Health News:Could Nicotine Patches Help Stave Off Memory Loss? 3Health News:Legionnaires' disease outbreak linked to hospital's decorative fountain 2Health News:Short Delay in Treating Blood Pressure Safe for Diabetics: Study 2Health News:Short Delay in Treating Blood Pressure Safe for Diabetics: Study 3
These are simple but effective single-dose, hands-off, ampulized applicators have revolutionized skin preparation in healthcare facilities....
... valuable tool in standardizing protocols for quality ... a procedure are supplied in a single ... are easier to be established and maintained. ... allowing the clinician to progress efficiently through ...
... Iodine (PVP-I) Prep Sponge Sticks ... Povidone Iodine, USP solution equivalent ... Plus Povidone Iodine (PVP-I) Scrub ... a 7.5% Povidone Iodine, USP ...
... preparation an important step ... Scrub Care brand Prevail-Fx Prevail ... efficacy and safety for your ... the highest level of infection ...
Medicine Products: